Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

v3.23.3
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Product Revenue
Product Cost of Sales
Gross Income
General and Administrative Expenses 1,334,690 1,554,244 4,202,594 4,296,119
Research and Development Expenses 1,912,322 1,803,232 4,907,196 6,596,942
Stock Based Compensation Expenses 595,576 352,417 2,341,915 581,663
Warrant Issuance Expenses 762,834
Loss from Operations (3,842,588) (3,709,893) (12,214,539) (11,474,724)
Other (Income) Expenses        
Interest and Dividend Income (139,056) (15,453) (339,731) (21,559)
(Gain)/Loss on Sale of Marketable Securities 500 1,200 714 4,849
Change in fair value of Marketable Securities (2,324) (1,899) 371 (1,754)
Change in fair value of Derivatives Liabilities (2,566,900) (2,251,700)
Change in fair value of Warrant Liabilities (5,356,000) (8,166,000)
Casualty Loss/(Gain) 178,198 178,198 (4,442)
Total Other Income (7,885,582) (16,152) (10,578,148) (22,906)
Income/(Loss) Before Income Tax 4,042,994 (3,693,741) (1,636,391) (11,451,818)
Income Tax Benefit/( Provision)
Net Income/(Loss) 4,042,994 (3,693,741) (1,636,391) (11,451,818)
Preferred Stock Dividends 1,158,051 1,690,180
Net Income/(Loss) Attributable to Common Stockholders $ 2,884,943 $ (3,693,741) $ (3,326,571) $ (11,451,818)
Basic net income/(loss) per common share $ 0.06 $ (0.09) $ (0.08) $ (0.30)
Diluted net income/(loss) per common share $ 0.06 $ (0.09) $ (0.08) $ (0.30)
Weighted average basic common shares outstanding 44,949,097 39,046,852 41,710,705 38,502,163
Weighted average diluted common shares outstanding 44,949,097 39,046,852 41,710,705 38,502,163